Carregant...
Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action
Fibroblast growth factor 21 (FGF21) is under investigation as a type 2 diabetes protein drug, but its efficacy is impeded by rapid in vivo clearance and by costly production methods. To improve the protein’s therapeutic utility, we recombinantly expressed FGF21 as a fusion with an elastin-like polyp...
Guardat en:
| Publicat a: | J Control Release |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5945213/ https://ncbi.nlm.nih.gov/pubmed/29551712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2018.03.015 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|